 |
인쇄하기
취소
|
Choong-wae Pharm to conduct local Phase III trials for mitigilinide, novel blood glucose lowering...
Choong-wae Pharm to conduct local Phase III trials for mitigilinide, novel blood glucose lowering agent
Following the recent NDA approval of mitigilinide, a novel short-acting insulin secretagogue to suppress postprandial hyperglycemia, filed by Kissei Pharmaceutical Co. in Japan, Choong-wae Pharm unveiled a plan to conduct its local phase III clinical trials in patients with type 2 diabetes...
Following the recent NDA approval of mitigilinide, a novel short-acting insulin secretagogue to suppress postprandial hyperglycemia, filed by Kissei Pharmaceutical Co. in Japan, Choong-wae Pharm unveiled a plan to conduct its local phase III clinical trials in patients with type 2 diabetes...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.